BIOSEEKER™
Behind every disease is a genetic blueprint. BioSeeker turns it into targets.
We map disease at its source — the genetic instructions required for it to replicate, persist, and evolve. BioSeeker is the AI engine that finds the sequences disease cannot afford to lose, then converts those discoveries into two deployable outputs: PTAP™ Guides for SAT therapeutics, and Primers and Probes for SeekIt™ Diagnostics.
Platform leverage
One AI engine powers two platforms.
BioSeeker combines comparative genomics, evolutionary analysis, and machine learning to find the conserved genetic sequences disease relies on to survive, replicate, and evade treatment. BioSeeker is the AI discovery engine inside PTAP™ — the Programmable Target Ablation Platform that uses these designs to create SAT therapeutics. In parallel, the same mapped targets drive Primers and Probes for SeekIt™ Diagnostics. One engine. Two product platforms.
The Engine & The Atlas
BioSeeker is the engine. The Global Disease Atlas is the living map it builds — and updates.
BioSeeker analyzes disease genomes to identify essential genetic targets — sequences that are critical to disease fitness and difficult to change under evolutionary pressure. Through iterative experimentation and validation, BioSeeker prioritizes the highest‑impact targets for therapeutic and diagnostic development.
The Global Disease Atlas is the living output of BioSeeker: a growing library of essential disease targets, mapped one disease at a time. Each entry is a complete genomic build with escape‑resistant sequences, coverage calculations, accessibility ratings, and ranked designs ready to advance as PTAP™ Guides for SAT therapeutics and Primers and Probes for SeekIt™ Diagnostics.
As BioSeeker continues to read new genetic data, the Atlas expands, refines, and evolves.
The Working Atlas
What BioSeeker delivers
Designed from the disease itself.
Most discovery platforms start with the patient — modeling cells, tissues, and biological responses to decide where to intervene. BioSeeker asks a different question: where is the disease itself most vulnerable, and which sequences can it not afford to lose? The output is not a theoretical prediction or a static ranked list. BioSeeker produces PTAP™ Guides ready to advance directly into SAT therapeutics, and Primers and Probes for SeekIt™ Diagnostics — built from conserved sequences the disease cannot escape without losing essential function.
CRISPR guide RNAs for SAT
Guide sequences directed toward essential disease targets. Each guide is built for broad coverage across variants, not a single strain or sample.
Primer / probe sets
Primer and probe sets designed from the same essential disease targets as our therapeutic guides — built for sequence-specific detection across variants, not just the strain circulating today. SeekIt™ designs are built to remain accurate as pathogens evolve.
The Global Disease Atlas and design-ready targets
The cumulative output is a growing library of mapped disease targets that continues to expand into new indications. For each mapped target, BioSeeker captures coverage, specificity, variant range, predicted escape risk, and platform‑ready sequence designs.
Inside BioSeeker
From sequence data to platform-ready designs.
What used to take years of lab iteration, BioSeeker now runs continuously in software. A four‑stage pipeline generates parallel therapeutic and diagnostic designs across every target in the Global Disease Atlas — updating as new sequence data arrives.
Ingest target space
BioSeeker gathers available sequence data for each target, including strains, variants, and isolates from public and partner genomic databases.
Input: raw sequence data
Identify essential targets
Comparative genomic analysis identifies genetic regions that remain stable across variants — sequences the disease depends on and cannot easily change.
Output: conserved loci
Screen for off-target hits
Every candidate is screened against host genomes, microbiome data, and known off-target sequences. Designs that cannot cleanly distinguish disease from healthy tissue are removed before they advance.
Output: specificity-validated candidates
Design creation and ranking
Machine learning models score candidates across the full target space, creating PTAP™ Guides for SAT therapeutics and Primers and Probes for SeekIt™ Diagnostics. The system is optimized for breadth, durability, and specificity.
Output: highest-priority target sequences
Advance platform-ready designs
The highest‑priority designs are routed into two product paths: PTAP™ Guides for SAT therapeutics and Primers and Probes for SeekIt™ Diagnostics.
Output: platform-ready therapeutic and diagnostic designs
The Seek System
Every deployment makes the system smarter and faster.
Each deployment improves the system. Each improvement accelerates the next response. BioSeeker maps the genome. SAT and SeekIt deploy against it. Field data — including sequences, performance, and escape candidates — returns to the Atlas, sharpening the next program. The platform compounds, and the advantage compounds with it.
- 01 Map vulnerabilities BioSeeker decodes conserved targets across the Atlas.
- 02 Deploy SAT therapeutics and SeekIt diagnostics.
- 03 Capture data Real-world sequences and performance feed back in.
- 04 Extend the Atlas The next program inherits everything the last one learned.
From the world’s sequence data to designed therapeutic and diagnostic assets — in six steps.
Cast the widest possible net.
Public genomic repositories and curated reference sets feed BioSeeker every available sequence for a target pathogen family. The system ingests the full target space — not a sample of it.
Find what evolution can’t change.
Multi-genome alignment surfaces the regions that are conserved across every variant — and a smaller subset that is ultra-conserved. These are the parts of the pathogen that cannot mutate without losing function.
Score every candidate.
Each conserved region is scored on three axes: breadth of coverage across known variants, evolutionary durability, and design specificity. The output is a ranked candidate list — not a hand-picked one.
Reject anything that looks like us.
Every surviving candidate is checked against the human genome. Sequences with meaningful homology are eliminated before they ever reach the lab. This is what keeps a therapeutic from cutting the host, and a diagnostic from cross-reacting with patient DNA.
Reject anything that looks like the microbiome.
The same gauntlet runs against the commensal microbiome — the bacterial, viral, and fungal communities that share our bodies. What survives both reference checks is unique to the pathogen, and only the pathogen.
One pipeline. Two platforms.
Surviving designs are routed downstream into deployable assets: PTAP™ multiplexed guides for the SAT therapeutic platform, and primers and probes for the SeekIt diagnostic platform. Same upstream engine. Two distinct product lines.
Specificity
Designed to hit disease. Not the host.
Most target discovery tools stop at identification. BioSeeker goes further — every candidate design is screened against host genomes, microbiome data, and potential off-target sequences before it advances. Designs that can’t distinguish disease from healthy sequence don’t make it through.
DISEASE ATLAS
The target library
A mapped collection of essential disease sequences across variants. This identifies what a therapeutic or diagnostic should target.
COUNTER SCREENS
Filter for specificity
Every target design is screened against host genomes and the human microbiome. Designs with potential cross-reactivity are removed.
HOST LIBRARIES
Built for the intended species
Human, livestock, aquaculture, and wildlife host genomes are built into the BioSeeker workflow, enabling designs to be evaluated against the relevant host(s).
EVERY DESIGN
Specificity from the start
Specificity is built into target selection and design, not added as a downstream check. No design advances without passing the counter‑screening process. This front‑loaded specificity is intended to reduce downstream attrition and increase the likelihood that candidates entering development are clinically actionable.
What we’ve mapped so far
145+ infectious diseases mapped.
Oncology underway.
We began with high-impact pathogens affecting human health, livestock, and the food supply. Traditional target discovery takes years per disease, requires expensive lab work, and often produces single-strain results that don’t hold across variants. BioSeeker’s 145+ maps represent a pre‑built head start: design‑ready targets across entire disease families, available now. Every new disease mapped enriches the Atlas and deepens the foundation for future therapeutic and diagnostic programs. Infectious disease laid the groundwork. Oncology is underway. Chronic and genetic disease follows.
Infectious diseases
Mapped target libraries across major infectious disease families. Each entry identifies essential genetic targets that can support both therapeutic and diagnostic design.
12
Hemorrhagic Fevers
Marburg · Ebola · Lassa · Crimean-Congo · Rift Valley · Hantaviruses
14
Respiratory Viruses
Influenza A/B (incl. HPAI) · RSV · SARS-CoV-2 · Metapneumovirus · Rhinoviruses
9
Orthopoxviruses
Variola · Mpox · Vaccinia · Cowpox · Camelpox · Monkeypox Clades I & II
18
Arboviruses
Dengue 1–4 · Zika · Chikungunya · Yellow Fever · West Nile · Japanese Encephalitis
22
Veterinary Pathogens
ASFV · CAPV · PRRSV · FMDV · Shrimp WSSV & IHHNV · Avian IBV · Newcastle Disease
11
Hepatitis & Chronic Viral
HBV · HCV · HDV · HPV High-Risk Types · HIV-1 Major Subtypes
16
Enteric & Zoonotic
Norovirus · Rotavirus · Nipah · Hendra · Coronaviruses of Livestock
43+
Additional Families
Bacterial, fungal, and parasitic pathogens of public health concern. Continuously added.
Cancer targets
Cancer is a sequence problem too. Tumors depend on oncogenic drivers and genetic fusions they cannot afford to lose — BioSeeker finds them. The same logic that works for viral disease applies here: target what cannot escape. The first oncology maps are underway.
30+
Cancer programs
NSCLC · Colorectal · Bladder · TNBC · Liver · Pancreatic · AML · Ovarian · Prostate · Endometrial · Renal · Lymphoma · Cervical · Gastric · Melanoma
Expanding the disease map
BioSeeker is built for sequence-driven disease. Chronic conditions, inherited disorders, and additional genetic disease classes are the next frontier.
The advantage
Built for speed, durability, and platform leverage.
One engine. Two product paths.
A single BioSeeker mapping can be leveraged into both SAT therapeutics and SeekIt diagnostics in the same disease area.
Designed for durability.
BioSeeker prioritizes essential genetic targets that are less likely to shift as disease evolves, supporting designs built to hold up across variants and over time.
Accelerated design at the sequence level.
When a new variant, disease class, or target emerges, BioSeeker can move directly from sequence data to design.
Programmable across sequence-driven disease.
If a disease has a sequence, BioSeeker can map it — from infectious disease today to oncology, chronic disease, and future therapeutic areas.
Build with BioSeeker
Advance your program with a mapped target base.
BioSeeker enables partners to explore new disease targets, map additional disease categories, and accelerate therapeutic, diagnostic, and R&D programs directly from sequence data. Partners receive platform‑ready PTAP™ Guides and SeekIt™ primer and probe sets derived from conserved essential targets — built for durability across variants, not single‑strain hits that evolutionary pressure will quickly invalidate. A single disease mapping can support both a therapeutic program and a diagnostic program: one engagement, two product paths. Have a target or disease category to map? Let’s talk.